top of page
  • EVI

GHIT supports further development of a new malaria vaccine candidate

This project aims to advance a new asexual blood-stage malaria vaccine candidate, based on the PfRipr5 protein of the malaria parasite.


The Global Health Innovative Technology Fund (GHIT) facilitates international partnerships that bring Japanese innovation, investment, and leadership to the global fight against infectious diseases and poverty in the developing world.

The three project partners -Ehime University, Japan, iBET, Portugal, and EVI, Germany- will test and compare different expression systems for the antigen and subsequently test the immunogenicity of the antigen formulated with different adjuvants in different model systems.

See also press release on GHIT webpage.


bottom of page